Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro (CLPT)
Pomerantz LLP has launched an investigation into ClearPoint Neuro, Inc. (NASDAQ: CLPT) regarding potential securities fraud or unlawful business practices by the company and its officers. The probe follows a significant decline in the company's stock price following disappointing clinical data disclosures. The investigation stems from a September 29, 2026, announcement by development partner uniQure N.V. (NASDAQ: QURE) regarding Phase I/II studies of ifezuntirgene inilparvovec for Huntington's disease. The treatment failed to reach statistical significance on a primary clinical measure at the 48-month mark, causing ClearPoint's shares to plummet by over 23% in a single day.
Topics: class action lawsuit clinical trial failure securities fraud investigation stock price drop